Dr. Fleming joined Alpha-9 as COO in October 2021, bringing 20 years of pharmaceutical experience with a focus on CMC leadership, spanning clinical trials to commercial supply. Previously, Dr. Fleming was the Chief Technology Officer at Collegium Pharmaceutical, where she oversaw commercial manufacturing, supply chain, formulation development, and quality assurance. Dr. Fleming earned her PhD from the School of Chemical and Biomolecular Engineering at Cornell University, where her research focused on novel drug delivery systems, and her BS degree in Chemical Engineering from the University of Massachusetts, Amherst.

• 

  Chief Operating Officer (COO) in Alpha-9 Oncology

  Harnessing the Power of Radiopharmaceuticals